RVNC Oct 2024 2.500 call
- Zacks
How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%
The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Reuters
Botox rival Revance to go private in $924 million deal
(Reuters) -Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought by privately held Crown Laboratories in a deal valued at $924 million, including debt, seeking scale to compete better with rivals in the aesthetic products market. Revance manufactures Daxxify, which competes with AbbVie's Botox, while Tennessee-based Crown makes various skincare and aesthetics products like SkinPen for microneedling and anti-aging cream StriVectin. Revance, which promotes its product to last twice as long as Botox, had initially priced it at a premium.
